Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
Sponsor: NYU Langone Health
Summary
The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-12-16
Completion Date
2027-04-30
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
Continuous Glucose Monitor
Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.
Blood Glucose Monitor
Self-administered according to investigator instruction.
Locations (1)
NYU Langone Hospital - Long Island
Mineola, New York, United States